Rojo, Ana I. and Buttari, Brigitta and Cadenas, Susana and Carlos, Ana Rita and Cuadrado, Antonio and Falcao, Ana Sofia and Lopez, Manuela G. and Georgiev, Milen I. and Grochot-Przeczek, Ana and Gumeni, Sentilijana and Jimenez-Villegas, Jose and Horbanczuk, Jaroslaw Olav and Konu, Ozlen and Lastres-Becker, Isabel and Levonen, Anna-Liisa and Maksimova, Viktorija and Michaeloudes, Charalambos and Mihaylova, Liliya V. and Mickael, Michel Edwar and Milisav, Irina and Miova, Biljana and Rada, Patricia and Santos, Marlene and Seabra, Miguel C. and Svob Strac, Dubravka and Tenreiro, Sandra and Trougakos, Ioannis P. and Dinkova-Kostova, Albena T. (2025) Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases. Redox Biology, 79.
Full text not available from this repository.Abstract
Non-communicable chronic diseases (NCDs) are most commonly characterized by age-related loss of homeostasis and/or by cumulative exposures to environmental factors, which lead to low-grade sustained generation of reactive oxygen species (ROS), chronic inflammation and metabolic imbalance. Nuclear factor erythroid 2-like 2 (NRF2) is a basic leucine-zipper transcription factor that regulates the cellular redox homeostasis. NRF2 controls the expression of more than 250 human genes that share in their regulatory regions a cis-acting enhancer termed the antioxidant response element (ARE). The products of these genes participate in numerous functions including biotransformation and redox homeostasis, lipid and iron metabolism, inflammation, proteostasis, as well as mitochondrial dynamics and energetics. Thus, it is possible that a single pharmacological NRF2 modulator might mitigate the effect of the main hallmarks of NCDs, including oxidative, proteostatic, inflammatory and/or metabolic stress. Research on model organisms has provided tremendous knowledge of the molecular mechanisms by which NRF2 affects NCDs pathogenesis. This review is a comprehensive summary of the most commonly used model organisms of NCDs in which NRF2 has been genetically or pharmacologically modulated, paving the way for drug development to combat NCDs. We discuss the validity and use of these models and identify future challenges.
Item Type: | Article |
---|---|
Impact Factor Value: | 10.7 |
Subjects: | Natural sciences > Biological sciences Medical and Health Sciences > Other medical sciences Natural sciences > Other natural sciences |
Divisions: | Faculty of Medical Science |
Depositing User: | Viktorija Maksimova |
Date Deposited: | 21 Jan 2025 10:19 |
Last Modified: | 21 Jan 2025 10:20 |
URI: | http://eprints3-ugd.westeurope.cloudapp.azure.com/id/eprint/35410 |